Biomarkers in systemic sclerosis

被引：11

作者：

Doran, J. P. ^{[1
]}

Veale, D. J. ^{[1
]}

机构：

[1] St Vincents Univ Hosp, Dept Rheumatol, Bone & Joint Unit, Dublin Acad Healthcare, Dublin 4, Ireland

来源：

RHEUMATOLOGY | 2008年 / 47卷

关键词：

Systemic sclerosis; Scleroderma; Raynauds phenomenon; Biomarkers; Collagen breakdown products; Acute-phase reactants; Immunoserological markers; Serum pro-brain natriuretic peptide; Serum N-terminal pro-brain natriuretic peptide; Endothelin;

D O I：

10.1093/rheumatology/ken270

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SSc is a CTD, which may cause critical organ fibrosis. It has a highly variable clinical presentation and course. While it is more common in females, this heterogeneity has led to significant problems with classification. Biomedical (clinical) and biomolecular markers to identify diagnostic, prognostic and therapeutic response have been elusive in part as a result of difficulties with classification and also due to the rarity of the disease. Existing biomarkers have been identified largely in small cohorts and larger cross-sectional or occasional longitudinal observational cohorts. The nature of biomarkers requires well-defined clinical characteristics and/or defined clinical outcomes and this has been extremely challenging to the international SSc research community. This brief review summarizes the current level of knowledge; however, it most importantly highlights the potential now to find biomarkers through a large, multicentre, international collaborative group approach.

引用

页码：V36 / V38

页数：3

共 17 条

[1] N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers [J].

Allanore, Y ;

Borderie, D ;

Meune, C ;

Cabanes, L ;

Weber, S ;

Ekindjian, OG ;

Kahan, A .

ARTHRITIS AND RHEUMATISM, 2003, 48 (12) :3503-3508

[2]

Allanore Y, 2003, J RHEUMATOL, V30, P68

[3]

Bryan C, 1996, BRIT J RHEUMATOL, V35, P1122

[4] Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis [J].

Cutolo, M ;

Pizzorni, C ;

Tuccio, M ;

Burroni, A ;

Craviotto, C ;

Basso, M ;

Seriolo, B ;

Sulli, A .

RHEUMATOLOGY, 2004, 43 (06) :719-726

[5]

Denton CP, 1995, BRIT J RHEUMATOL, V34, P1048

[6] Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1,012 Italian patients [J].

Ferri, C ;

Valentini, G ;

Cozzi, F ;

Sebastiani, M ;

Michelassi, C ;

La Montagna, G ;

Bullo, A ;

Cazzato, M ;

Tirri, E ;

Storino, F ;

Giuggioli, D ;

Cuomo, G ;

Rosada, M ;

Bombardieri, S ;

Todesco, S ;

Tirri, G .

MEDICINE, 2002, 81 (02) :139-153

[7] Disease severity of 100 patients with systemic sclerosis over a period of 14 years:: using a modified Medsger scale [J].

Geirsson, AJ ;

Wollheim, FA ;

Åkesson, A .

ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (12) :1117-1122

[8] Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon [J].

Istok, R ;

Czirják, L ;

Lukác, J ;

Stancíková, M ;

Rovensky, J .

RHEUMATOLOGY, 2001, 40 (02) :140-146

[9]

Komura K, 2007, J RHEUMATOL, V34, P353

[10] Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population [J].

Mayes, MD ;

Lacey, JV ;

Beebe-Dimmer, J ;

Gillespie, BW ;

Cooper, B ;

Laing, TJ ;

Schottenfeld, D .

ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2246-2255

← 1 2 →